Enzymatica Future Growth

Future criteria checks 5/6

Enzymatica is forecast to grow earnings and revenue by 102.7% and 59.6% per annum respectively while EPS is expected to grow by 7.7% per annum.

Key information

102.7%

Earnings growth rate

7.7%

EPS growth rate

Pharmaceuticals earnings growth66.0%
Revenue growth rate59.6%
Future return on equityn/a
Analyst coverage

Low

Last updated19 Jul 2024

Recent future growth updates

Recent updates

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 20
Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 22
Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Feb 18
Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Jan 12
Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Jul 20
Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)

May 02
Revenue Downgrade: Here's What Analysts Forecast For Enzymatica AB (STO:ENZY)

Earnings and Revenue Growth Forecasts

OM:ENZY - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202619146-58522
12/31/2025114-9-43-202
12/31/202449-55-45-451
6/30/202445-56-45-45N/A
3/31/202447-54-36-35N/A
12/31/202351-50-41-40N/A
9/30/202352-58-65-65N/A
6/30/202357-62-56-55N/A
3/31/202358-66-69-67N/A
12/31/202249-69-68-65N/A
9/30/202251-57-49-44N/A
6/30/202248-50-59-54N/A
3/31/202244-55-51-47N/A
12/31/202157-45-42-36N/A
9/30/202181-35-46-38N/A
6/30/202194-31-26-18N/A
3/31/2021101-23-13-5N/A
12/31/2020111-13-15-11N/A
9/30/202091-18-4-3N/A
6/30/202082-24-17-16N/A
3/31/202075-28-27-27N/A
12/31/201961-41-38-38N/A
9/30/201958-43-36-36N/A
6/30/201952-45-39-38N/A
3/31/201951-45-43-43N/A
12/31/201853-43-29-29N/A
9/30/201853-41-30-29N/A
6/30/201864-35-26-25N/A
3/31/201865-30N/A-15N/A
12/31/201759-31N/A-23N/A
9/30/201752-43N/A-27N/A
6/30/201739-46N/A-35N/A
3/31/201738-48N/A-42N/A
12/31/201636-45N/A-38N/A
9/30/201636-39N/A-48N/A
6/30/201631-42N/A-45N/A
3/31/201629-40N/A-38N/A
12/31/201528-41N/A-38N/A
9/30/201526-42N/A-39N/A
6/30/201525-38N/A-38N/A
3/31/201524-35N/A-42N/A
12/31/201419-32N/A-41N/A
9/30/201417-25N/A-34N/A
6/30/201413-24N/A-28N/A
3/31/201412-20N/A-21N/A
12/31/201310-16N/A-18N/A
9/30/20136-14N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENZY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: ENZY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ENZY is expected to become profitable in the next 3 years.

Revenue vs Market: ENZY's revenue (59.6% per year) is forecast to grow faster than the Swedish market (1% per year).

High Growth Revenue: ENZY's revenue (59.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENZY's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.